| Name | Title | Contact Details |
|---|---|---|
Brian Gaon |
Information Security Officer (ISO) | Profile |
Based in Austin, Texas, TimberTown Specialty Building Products supplies high quality lumber and building materials for a wide variety of residential and commercial projects. Our products range from high-end exotic hardwoods, softwoods and composites; often specially milled for different applications. The types of projects we supply can be as simple as a small residential outdoor cedar deck, to the very complex hardwood siding for a multi-million dollar custom home or a rooftop patio on a downtown high-rise. With such a large and diverse client base, we excel in providing exceptional service for contractors and commercial builders, architects, designers and their clients.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.